Drug delivery trends in clinical trials and translational medicine: Updated analysis of clinicaltrials.gov database

Journal of Pharmaceutical Sciences

Volumn 98, Issue 6, 2009, Pages 1928-1934

  Ho, Rodney J Y ^a   Chien, Jenny Y ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Biotechnology; DNA oligonucleotide delivery; Drug targeting; Drug transport; Formulation; Gene delivery; Liposomes; Nanoparticles; Peptide delivery; Polymeric drug delivery systems

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DATA BASE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY; LIVER; NONHUMAN; NOTE; TARGET ORGAN; TOXICITY;

EID: 67049114280     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21649     Document Type: Article

References (12)

1. Csellar M, Perrow K. 2007. New Survey Finds Strong Public Interest in Prescription Drug Safety Issues: Americans Trust FDA, but express conflicting views about how to manage safety risks. ed.: American University's Center for Congressional and Presidential Studies. [cited 2008 October 20] Available from: http://www.prnews-wire.com/mnr/dialogue/29804/.
2. Woodcock J, Woosley R. 2008. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59:1-12. (Pubitemid 351287920)
3. Chien JY, Ho RJ. 2008. Drug delivery trends in clinical trials and translational medicine. J Pharm Sci 97:2543-2547.
4. Ho RJ, Gibaldi M. 2003. Not all protein drugs and vaccines of the same name are identical. In: Ho RJ, Gibaldi M, editors. Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs. Hoboken, NJ: John Wiley and Sons. pp. 2-9.
5. Ho RJ, Gibaldi M. 2003. Antibodies and Derivatives. In: Ho RJ, Gibaldi M, editors. Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs. Hoboken, NJ: John Wiley and Sons. pp. 271-311.
6. Carter PJ. 2006. Potent antibody therapeutics by design. Nat Rev 6:343-357.
7. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758. (Pubitemid 34525533)
8. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K. 2004. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and Fc[gamma]RIIIa. J Mol Biol 336:1239-1249. (Pubitemid 38229710)
9. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. 2006. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26:5340-5346. (Pubitemid 44318386)
10. Jack CR Jr, Marjanska M, Wengenack TM, Reyes DA, Curran GL, Lin J, Preboske GM, Poduslo JF, Garwood M. 2007. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: A new tool in Alzheimer's disease research. Neuroscientist 13:38-48. (Pubitemid 46052752)
11. Robinson SR, Bishop GM, Lee HG, Munch G. 2004. Lessons from the AN 1792 Alzheimer vaccine: Lest we forget. Neurobiol Aging 25:609-615. (Pubitemid 38686482)
12. Brody DL, Holtzman DM. 2008. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175-193.